The Journal of dermatological treatment最新文献_第9页

Early response to ivarmacitinib and its impact on long-term efficacy in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase-III trial. 伊瓦马替尼对中重度特应性皮炎患者的早期反应及其对长期疗效的影响：一项iii期试验的事后分析

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-07-15 DOI: 10.1080/09546634.2026.2637340

Jinbo Chen, Feng Hu, Ping Zhang, Liuqing Chen

{"title":"Early response to ivarmacitinib and its impact on long-term efficacy in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase-III trial.","authors":"Jinbo Chen, Feng Hu, Ping Zhang, Liuqing Chen","doi":"10.1080/09546634.2026.2637340","DOIUrl":"10.1080/09546634.2026.2637340","url":null,"abstract":"Background: Ivarmacitinib, also known as SHR0302, is a novel highly selective Janus kinase 1 inhibitor that suppresses cytokine signaling pathways involved in the pathogenesis of atopic dermatitis (AD).Objective: We aimed to explore the early response to ivarmacitinib in patients with moderate-to-severe AD and its impact on long-term efficacy.Methods: This post hoc analysis included all patients receiving ivarmacitinib in the phase-III trial (NCT04875169). Patients were divided into early and nonearly responders, depending on whether they achieved an Eczema Area and Severity Index (EASI) 75 response at week (W) 4.Results: Among the 225 patients included, 83 (36.9%) were classified as early responders and 142 (63.1%) as nonearly responders. The EASI 75 (81.9% vs. 47.2%, p < 0.001) and Investigator's Global Assessment (IGA) (56.6% vs. 28.9%, p < 0.001) response rates at W16 were higher in early responders. Additionally, early responders had higher EASI 90, EASI 100, and Scoring Atopic Dermatitis 75 and 90 response rates throughout W8 to W52. The changes in Dermatology Life Quality Index and Patient-Oriented Eczema Measure scores from baseline were greater in early responders from W8 to W52.Conclusion: Early response to ivarmacitinib at W4 yields better long-term efficacy in patients with moderate-to-severe AD.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2637340"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148451159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study. CG2001在中国成年男性雄激素性脱发患者中的安全性、耐受性和药代动力学：一项随机、双盲、安慰剂对照、单剂量和多剂量的1期临床研究

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-02-01 DOI: 10.1080/09546634.2026.2616198

Yanting Li, Baohui Yu, Suping Niu, Ziyan Ding, Qun Gu, Hui Zhang, Rui Ding, Cheng Zhou, Fang Men, Yian Liu, Wenyan Zhao, Liming Chen, Shuang Li, Qian Wang, Meng Xiao, Fan Huang, Binyi Hu, Jiaojiao Zhang, Jianzhong Zhang, Yi Fang

{"title":"Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study.","authors":"Yanting Li, Baohui Yu, Suping Niu, Ziyan Ding, Qun Gu, Hui Zhang, Rui Ding, Cheng Zhou, Fang Men, Yian Liu, Wenyan Zhao, Liming Chen, Shuang Li, Qian Wang, Meng Xiao, Fan Huang, Binyi Hu, Jiaojiao Zhang, Jianzhong Zhang, Yi Fang","doi":"10.1080/09546634.2026.2616198","DOIUrl":"10.1080/09546634.2026.2616198","url":null,"abstract":"Objectives: Compared with placebo, this phase I study evaluated the safety, tolerability, and pharmacokinetics of CG2001, a novel isopropyl alcohol-free minoxidil-finasteride combination topical foam, in Chinese males with androgenetic alopecia (AGA).Methods: In this randomized, double-blind, placebo-controlled trial, 44 subjects received single and multiple doses across five cohorts with varying finasteride concentrations (0.025%-0.1%) and frequencies. Safety, tolerability, and pharmacokinetics were evaluated. The concentrations of minoxidil-finasteride were both measured.Results: The result shows that CG2001 was safe and well-tolerated, with no serious adverse events. Systemic minoxidil exposure was consistent across most dosages, while finasteride exposure increased dose- and frequency-dependently, though it remained markedly lower than that reported with oral administration. Steady state was achieved for both drugs after 7 days.Conculsions: The favorable safety profile and reduced systemic finasteride exposure position CG2001 as a promising alternative, supporting further clinical development in a phase IIa trial, and provide a pharmacokinetic foundation for subsequent efficacy trials in patients with AGA.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2616198"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146101264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complete clearance of high-impact sites with risankizumab in patients with psoriasis: a 2-year real-world retrospective multicenter cohort study. 利桑单抗对银屑病患者高影响部位的完全清除：一项为期2年的真实世界回顾性多中心队列研究

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-05-06 DOI: 10.1080/09546634.2026.2668213

Margarida Contente, Ana Luísa João, Martim Luz, Pedro Mendes-Bastos, Ângela Roda, Luiz Leite, Joana Valério, Ana Ferreirinha, Bárbara Leal, Maria João Paiva Lopes, Rita Pimenta, Paulo Ferreira, Tiago Torres

{"title":"Complete clearance of high-impact sites with risankizumab in patients with psoriasis: a 2-year real-world retrospective multicenter cohort study.","authors":"Margarida Contente, Ana Luísa João, Martim Luz, Pedro Mendes-Bastos, Ângela Roda, Luiz Leite, Joana Valério, Ana Ferreirinha, Bárbara Leal, Maria João Paiva Lopes, Rita Pimenta, Paulo Ferreira, Tiago Torres","doi":"10.1080/09546634.2026.2668213","DOIUrl":"10.1080/09546634.2026.2668213","url":null,"abstract":"Objectives: Plaque psoriasis frequently involves high-impact anatomical sites such as the scalp, nails, and palmoplantar regions, which are associated with significant functional impairment and reduced quality of life. Evidence on the long-term effectiveness of biologic therapies in these locations in real-world settings remains limited. This study aimed to evaluate the real-world effectiveness and safety outcomes of risankizumab in achieving complete clearance of psoriasis affecting high-impact sites over a 2-year period.Methods: We conducted a retrospective multicenter cohort study including adult patients with plaque psoriasis who initiated risankizumab between January 2020 and December 2023 across six dermatology centers. Effectiveness was assessed as the proportion of patients achieving complete clearance (Physician Global Assessment score of 0) in scalp, nail, and palmoplantar psoriasis.Results: Among 459 patients treated with risankizumab, 232 (50.5%) had involvement of at least one high-impact site at baseline. Complete clearance at 2 years was achieved in 72.5% of patients with scalp involvement, 64.7% of those with nail psoriasis, and 52.2% of those with palmoplantar disease. Adverse events were infrequent and not treatment-limiting.Conclusions: These findings support the effectiveness of risankizumab in high-impact psoriasis sites in real-world clinical practice.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2668213"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Raising the bar of efficacy in Atopic Dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 years. 提高特应性皮炎的疗效标准：在2年多的时间里，lebrikizumab治疗的第16周应答者有深度反应。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-03-12 DOI: 10.1080/09546634.2026.2631233

Eric Simpson, Tilo Biedermann, Leon Kircik, Raj Chovatiya, Ignasi Figueras, Gaia Gallo, Marta Casillas, Yuxin Ding, Chenjia Xu, Chaoran Hu, Evangeline Pierce, Helena Agell, Christian Vestergaard

{"title":"Raising the bar of efficacy in Atopic Dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 years.","authors":"Eric Simpson, Tilo Biedermann, Leon Kircik, Raj Chovatiya, Ignasi Figueras, Gaia Gallo, Marta Casillas, Yuxin Ding, Chenjia Xu, Chaoran Hu, Evangeline Pierce, Helena Agell, Christian Vestergaard","doi":"10.1080/09546634.2026.2631233","DOIUrl":"10.1080/09546634.2026.2631233","url":null,"abstract":"Background: Lebrikizumab, a high-affinity monoclonal antibody targeting interleukin-13, effectively treats moderate-to-severe atopic dermatitis (AD).Methods: Lebrikizumab-treated patients in ADvocate1&2 achieving per-protocol response-IGA (0,1) or EASI 75 at Week 16-were re-randomized 2:2:1 to lebrikizumab 250 mg every 2 weeks (Q2W), Q4W, or placebo (lebrikizumab withdrawal). Patients completing Week 52 could enroll in the extension study, ADjoin. Deep response was defined as IGA (0), EASI 100, or Pruritus Numerical Rating Scale score 0 or 1 (NRS [0,1]). This analysis reports as-observed data.Results and conclusions: From Week 16-104, among IGA (0,1) responders at Week 16, increased proportions of patients achieved IGA (0) with lebrikizumab Q2W (33.8% [Nx = 77] to 52.3% [Nx = 44]) and Q4W (29.9% [Nx = 77] to 45.5% [Nx = 55]); among EASI 75 responders at Week 16, increased proportions of patients achieved EASI 100 with lebrikizumab Q2W (21.4% [Nx = 112] to 39.7% [Nx = 68]) and Q4W (20.0% [Nx = 115] to 41.3% [Nx = 80]); and among per-protocol responders, increased proportions of patients reported Pruritus NRS (0,1) with lebrikizumab Q2W (35.2% [Nx = 108] to 57.4% [Nx = 61]) and Q4W (34.2% [Nx = 114] to 55.4% [Nx = 65]). Continued lebrikizumab treatment for 2 years resulted in approximately half of per-protocol responders achieving complete skin clearance (IGA 0) and itch relief, raising the bar of treatment goals for AD patients.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2631233"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147438555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter to the Editor: sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis. 致编辑的信：持续使用阿布替尼治疗中重度特应性皮炎。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-06-18 DOI: 10.1080/09546634.2026.2690324

Yusra Hidayat

引用次数: 0

Use of narrowband-UVB phototherapy as long-term treatment of urticaria pigmentosa: a case series. 使用窄带uvb光疗作为色素性荨麻疹的长期治疗：一个病例系列。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-09-02 DOI: 10.1080/09546634.2026.2724627

Carli Tucci, Zasca-Aisha Ristianto, Elisabeth G Richard, John G Zampella

{"title":"Use of narrowband-UVB phototherapy as long-term treatment of urticaria pigmentosa: a case series.","authors":"Carli Tucci, Zasca-Aisha Ristianto, Elisabeth G Richard, John G Zampella","doi":"10.1080/09546634.2026.2724627","DOIUrl":"10.1080/09546634.2026.2724627","url":null,"abstract":"Objectives: Urticaria pigmentosa (UP) is the most common form of cutaneous mastocytosis. UP presents with pruritic, red-brown macules and papules, and can be associated with systemic involvement. Currently, there is no cure for UP. Treatment options have been historically limited to antihistamines, which are effective for symptoms but not cosmesis of the lesions. While phototherapy is a recognized treatment for cutaneous mastocytosis, there is sparse evidence addressing the efficacy of narrowband UVB (NB-UVB) phototherapy for UP specifically. We describe three cases of long-standing UP successfully treated with NB-UVB.Methods: A retrospective chart review was performed to collect demographic characteristics, disease features, prior treatments, phototherapy parameters, adverse events, pruritus severity, and clinical response using investigator global assessment.Results: All three patients demonstrated clinical improvement with NB-UVB despite differences in disease duration, prior treatment history, and phototherapy adherence. Pruritus resolved during therapy for all patients, and two patients had documented improvement in lesion appearance. Treatment was well tolerated, with adverse events limited to mild, transient erythema in two patients and no severe or long-term complications documented.Conclusions: These cases support NB-UVB as a durable and well-tolerated treatment option for selected adult patients with UP, particularly those with inadequate response to conventional therapies or need for adjunctive treatment.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2724627"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148882006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reply to Gargiulo et al.: Dose-stratified real-world effectiveness of JAK1 inhibitors in atopic dermatitis. 回复Gargiulo等人：JAK1抑制剂在特应性皮炎中的剂量分层实际有效性。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-02-16 DOI: 10.1080/09546634.2026.2627103

Abdullah Demirbaş, Mustafa Esen, Esin Diremsizoglu, Gözde Ulutaş Demirbaş

引用次数: 0

Efficacy and safety of tranilast combined with minocycline in the treatment of moderate-to-severe rosacea: a prospective, randomized controlled study. 曲尼司特联合米诺环素治疗中重度酒渣鼻的疗效和安全性：一项前瞻性、随机对照研究。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2025-12-22 DOI: 10.1080/09546634.2025.2597711

Jingchen Liang, Ying Chen, Mengyao Yang, Hongshan Liu, Yale Liu, Shujuan He, Zhao Wang, Weihui Zeng

{"title":"Efficacy and safety of tranilast combined with minocycline in the treatment of moderate-to-severe rosacea: a prospective, randomized controlled study.","authors":"Jingchen Liang, Ying Chen, Mengyao Yang, Hongshan Liu, Yale Liu, Shujuan He, Zhao Wang, Weihui Zeng","doi":"10.1080/09546634.2025.2597711","DOIUrl":"10.1080/09546634.2025.2597711","url":null,"abstract":"Background: Rosacea is a common chronic inflammatory skin disease. Mast cells are implicated in the pathogenesis of rosacea. However, the therapeutic potential of tranilast, a mast cell membrane stabilizer, remains unexplored. This study aims to evaluate the efficacy and safety of tranilast monotherapy and in combination with minocycline in patients with moderate-to-severe rosacea.Methods: This study has been registered on ClinicalTrials.gov (Registration No. NCT06307223). All enrolled patients with rosacea were randomly assigned to receive tranilast, minocycline, or a combination of both. Tranilast (0.1 g, three times daily) and minocycline (50 mg, once daily) were administered for 12 weeks, with follow-up every two weeks.Results: Forty-five patients completed the study. At week 12, the combination group showed a significantly higher IGA success rate (93.33%) compared to the tranilast (53.33%) and minocycline (46.67%) groups (p < 0.05). The secondary endpoints, such as CEA success rate, erythema index, and erythema score, also favored the combination group over minocycline group (p = 0.021, 0.030, and 0.024, respectively).Conclusion: In our study, patients with moderate to severe rosacea treated with tranilast showed a favorable clinical response and experienced no serious adverse events. The combination therapy yielded better outcomes than minocycline monotherapy, especially in improving facial erythema.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2597711"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145807186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies. 从其他先进疗法转向guselkumab、肿瘤坏死因子抑制剂、白介素-17抑制剂或阿普雷米司特后银屑病的标签持久性。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-02-24 DOI: 10.1080/09546634.2026.2631903

Maryia Zhdanava, Timothy Fitzgerald, Porpong Boonmak, Dominic Pilon, Samuel Schwartzbein, Béatrice Libchaber, Steven R Feldman

{"title":"On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies.","authors":"Maryia Zhdanava, Timothy Fitzgerald, Porpong Boonmak, Dominic Pilon, Samuel Schwartzbein, Béatrice Libchaber, Steven R Feldman","doi":"10.1080/09546634.2026.2631903","DOIUrl":"10.1080/09546634.2026.2631903","url":null,"abstract":"Objective: To compare on-label persistence among adults with psoriasis who switched from other advanced therapies to guselkumab versus subcutaneous tumor necrosis factor inhibitors (SC TNFi), subcutaneous interleukin-17 inhibitors (SC IL-17i), or apremilast.Materials and methods: This retrospective cohort study used U.S. claims data from the IQVIA PharMetrics® Plus database (2016- 2023). Overlap propensity score weights were used to balance cohorts on baseline characteristics. On-label persistence was defined as the absence of drug discontinuation (event) and any dose change relative to the U.S. label (censoring). Survival analyses were used to assess on-label persistence from the start of the maintenance phase.Results: At 12, 18, and 24 months after the start of the maintenance phase, respectively, on-label persistence was 190%, 180%, and 179% more likely on guselkumab versus SC TNFi; 78%, 87%, and 91% more likely on guselkumab versus SC IL-17i; and 187%, 199%, and 193% more likely on guselkumab versus apremilast (all p < 0.001).Conclusions: Patients experiencing suboptimal outcomes with other psoriasis-indicated advanced therapies achieved higher on-label persistence after switching to guselkumab, raising the potential for improved disease control relative to other treatment options.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2631903"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147278170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative efficacy, recovery, and pigmentary safety of radiofrequency microneedling and fractional carbon dioxide laser for facial atrophic acne scars: a prospective randomized split-face trial. 射频微针和二氧化碳激光治疗面部萎缩性痤疮疤痕的疗效、恢复和色素安全性的比较：一项前瞻性随机分脸试验。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-06-18 DOI: 10.1080/09546634.2026.2687842

Wei Li, Chunjiao Zheng, Xiaohai Yuan, Zongzhou Wu, Congying Li, Caixia Li, Zhixiang Hu, Bing Nie, Yu Shi, Qian Yu

{"title":"Comparative efficacy, recovery, and pigmentary safety of radiofrequency microneedling and fractional carbon dioxide laser for facial atrophic acne scars: a prospective randomized split-face trial.","authors":"Wei Li, Chunjiao Zheng, Xiaohai Yuan, Zongzhou Wu, Congying Li, Caixia Li, Zhixiang Hu, Bing Nie, Yu Shi, Qian Yu","doi":"10.1080/09546634.2026.2687842","DOIUrl":"10.1080/09546634.2026.2687842","url":null,"abstract":"Objective: To compare efficacy, recovery, pigmentary safety, and patient-reported outcomes of radiofrequency microneedling (RFMN) and fractional carbon dioxide laser (FCO2) for facial atrophic acne scars.Methods: In this prospective, randomized, split-face, evaluator-blinded exploratory trial, 33 patients were enrolled, and 30 completed the study. Each facial side was assigned to RFMN or FCO2. Three treatment sessions were performed at 8-week intervals. The primary endpoint was the change in Echelle d'Evaluation Clinique des Cicatrices d'Acné (ECCA) score. Secondary outcomes included physician-rated improvement, satisfaction, Dermatology Life Quality Index, pain, recovery-related outcomes, and adverse events.Results: Both modalities significantly improved acne scars over time. Mean ECCA scores decreased from 54.73 to 30.53 with RFMN and from 53.67 to 31.03 with FCO2, without a significant between-treatment difference. Physician-rated improvement was comparable. RFMN showed higher efficacy satisfaction after the first session and higher safety satisfaction at all follow-up assessments. RFMN was associated with shorter erythema, pain, swelling, and scab-detachment durations and fewer post-inflammatory hyperpigmentation events.Conclusions: Both treatments improved facial atrophic acne scars in this exploratory split-face sample. RFMN offered faster recovery, fewer pigmentary events, and higher safety satisfaction.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2687842"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148274414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0